CEL-SCI (CVM) Competitors $7.44 -0.79 (-9.60%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.70 +0.26 (+3.49%) As of 08/8/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. ENGN, GNFT, CTMX, EPRX, VTYX, TVGN, CRBU, CYBN, OGI, and DMACShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include enGene (ENGN), GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Semper Paratus Acquisition (TVGN), Caribou Biosciences (CRBU), Cybin (CYBN), Organigram Global (OGI), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors enGene GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Semper Paratus Acquisition Caribou Biosciences Cybin Organigram Global DiaMedica Therapeutics CEL-SCI (NYSE:CVM) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer CVM or ENGN? enGene has a consensus price target of $23.29, indicating a potential upside of 532.76%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is CVM or ENGN more profitable? enGene's return on equity of -32.60% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% enGene N/A -32.60%-28.26% Which has more volatility and risk, CVM or ENGN? CEL-SCI has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Do institutionals and insiders have more ownership in CVM or ENGN? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 9.9% of CEL-SCI shares are owned by insiders. Comparatively, 10.4% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, CVM or ENGN? enGene is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$12.61-0.59enGeneN/AN/A-$55.14M-$1.65-2.23 Does the media favor CVM or ENGN? In the previous week, enGene had 6 more articles in the media than CEL-SCI. MarketBeat recorded 8 mentions for enGene and 2 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.54 beat enGene's score of 0.25 indicating that CEL-SCI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryenGene beats CEL-SCI on 11 of the 14 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$39.59M$281.95M$5.44B$20.70BDividend YieldN/AN/A4.61%3.67%P/E Ratio-15.50N/A29.7628.45Price / SalesN/A462.25449.1256.07Price / CashN/A22.4436.4223.21Price / Book49.608.908.184.33Net Income-$26.92M-$115.81M$3.26B$996.14M7 Day Performance-21.27%-2.21%6.88%1.98%1 Month Performance165.71%-2.05%1.00%-0.84%1 Year Performance-79.50%-4.18%28.85%14.36% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.9979 of 5 stars$7.44-9.6%N/A-79.5%$39.59MN/A-15.5043ENGNenGene3.2835 of 5 stars$3.82-0.3%$23.29+509.6%-48.2%$195.73MN/A-2.3231High Trading VolumeGNFTGENFIT1.7417 of 5 stars$3.79-0.3%$13.00+243.0%-8.8%$190.01M$76.77M0.00120Gap UpCTMXCytomX Therapeutics3.9889 of 5 stars$2.39+1.7%$5.75+140.6%+99.2%$189.46M$138.10M4.98170News CoverageGap DownEPRXEupraxia Pharmaceuticals2.7427 of 5 stars$5.37+2.0%$11.00+105.0%+108.7%$189.15MN/A-7.0629VTYXVentyx Biosciences2.7809 of 5 stars$2.72+3.4%$10.00+267.6%+41.9%$187.15MN/A-1.5530News CoverageEarnings ReportUpcoming EarningsAnalyst UpgradeGap UpTVGNSemper Paratus Acquisition3.6513 of 5 stars$0.99-0.7%$10.00+907.5%+46.7%$183.88MN/A0.003CRBUCaribou Biosciences2.4382 of 5 stars$2.10+7.7%$8.50+304.8%-14.4%$181.36M$9.99M-1.30100CYBNCybin2.845 of 5 stars$7.68+1.6%$85.00+1,006.8%N/A$181.17MN/A-1.7550OGIOrganigram Global1.2332 of 5 stars$1.38+3.8%N/A-6.2%$178.26M$117.47M13.80860Upcoming EarningsDMACDiaMedica Therapeutics1.425 of 5 stars$4.36+5.8%$10.75+146.6%+39.4%$176.68MN/A-6.8120Gap Up Related Companies and Tools Related Companies enGene Competitors GENFIT Competitors CytomX Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Ventyx Biosciences Competitors Semper Paratus Acquisition Competitors Caribou Biosciences Competitors Cybin Competitors Organigram Global Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
